Nasdaq: APGE−6.11% 24h move
Price before$82.81May 26, 2026, 4:00 PM ET
First trade after$67.00May 27, 2026, 6:39 AM ET
24h later$77.75May 28, 2026, 4:42 AM ET
Complete Announced during: Premarket · announced Wed 6:37a ET (premarket); before = Tue close; first trade Wed 6:39a ET; time = SEC 8-K acceptance
Apogee Therapeutics (Nasdaq: APGE) reported results from a Phase 2 trial of zumilokibart in atopic dermatitis on May 27, 2026. The company said the trial met its primary endpoint (p<0.001).
Trial details
- Drug
- Zumilokibart
- Treats
- Atopic Dermatitis
- Phase
- Phase 2
- Result
- Met endpointSecondary endpoints include Validated Investigator’s Global Assessment (IGA) 0/1, EASI-90, Itch Numeric Rating Scale (I-NRS ≥4), EASI-100, and Very Low Disease Activity (vLDA; EASI-90 + I-NRS 0/1) at Week 16. ●The trial met its primary endpoint, with mid- and high-doses of zumilokibart demonstrating comparable efficacy and both doses outperforming low dose and placebo with EASI-75 scores at…p-value p<0.001Figures as reported by the sponsor or registry; not calculated by DrugTrials.org.
- Safety
- Based on these dose optimization results and subject to regulatory interactions, Apogee plans to move forward with the mid-dose, which achieved the best clinical activity of the three doses tested and was well-tolerated, in its Phase 3 trials.
- Sponsor
- Apogee Therapeutics Nasdaq: APGE
- Dates
- Announced May 27, 2026, 6:37 AM ET (SEC 8-K filing time)
About this trial
This Phase 2 trial tested Zumilokibart in Atopic Dermatitis. Apogee Therapeutics reported that the trial met its primary endpoint (p-value: p<0.001).
Sources
- Source: SEC EDGAR 8-K (EX-99.1)
For information only. Not investment or medical advice. Prices are historical, from consolidated market data, and may contain errors. Always check the original source.